From GlobeNewswire: 2025-02-27 08:00:00

Nautilus Biotechnology, Inc. reported total operating expenses of $20.0 million for Q4 2024, on par with Q4 2023, with an additional $0.9 million from last quarter. A reduction in headcount by 16% was announced to align resources for key development goals. The company expects to launch its proteome analysis platform in late 2026.

In 2024, Nautilus Biotechnology experienced a net loss of $17.6 million for Q4 and $70.8 million for the fiscal year. Operating expenses were $81.5 million for 2024, a 7% increase from 2023. Cash, cash equivalents, and investments stood at $206.3 million as of December 31, 2024.

For fiscal year 2025, Nautilus anticipates operating expenses to be similar to or lower than 2024 levels. The company’s cash, cash equivalents, and investments of $206.3 million as of December 31, 2024, are expected to provide runway through 2027. A conference call discussing financial results and outlook will be held on February 27, 2025.

Nautilus Biotechnology, Inc., based in Seattle and San Carlos, is focused on creating a platform technology to quantify and unlock proteome complexity. Forward-looking statements in the press release detail the company’s expectations for business operations, financial performance, and product platform launch. Risks and uncertainties related to product development are noted. Investors are encouraged to review public information for updates.



Read more at GlobeNewswire:: Nautilus Biotechnology Reports Fourth Quarter and Fiscal